We narrowed to 2,862 results for: Lox

#177673-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#105715-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s (#105715). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO-Synaptophysin-GCaMP6s plasmid DNA. EF1a-driven, Cre-dependent GCaMP6s fused to the presynaptic protein synaptophysin. These AAV preparations are suitable purity for injection into animals.

Rylan Larsen

Oct. 20, 2020

Academic Institutions and Nonprofits only

#52536-AAV1

Ready-to-use AAV1 particles produced from rAAV-CAG::FLEX-rev:: hM4D-2a-GFP (#52536). In addition to the viral particles, you will also receive purified rAAV-CAG::FLEX-rev:: hM4D-2a-GFP plasmid DNA. CAG driven, Cre-dependent expression of hM4D and GFP. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al Nature. 2012 Aug 9;488(7410):172-7. doi:

Dec. 18, 2024

Academic Institutions and Nonprofits only

#45186-AAV9

Ready-to-use AAV9 particles produced from AAV-EF1a-BbChT (#45186). In addition to the viral particles, you will also receive purified AAV-EF1a-BbChT plasmid DNA. Brainbow construct encoding mCherry and mTFP, both in reverse orientation between mutant Lox sites. These AAV preparations are suitable purity for injection into animals.

Dawen Cai, Joshua Sanes

Cai et al Nat Methods. 2013 May 5;10(6):540-7. doi

April 13, 2018

Academic Institutions and Nonprofits only

#45185-AAV9

Ready-to-use AAV9 particles produced from AAV-EF1a-BbTagBY (#45185). In addition to the viral particles, you will also receive purified AAV-EF1a-BbTagBY plasmid DNA. Brainbow construct encoding farnesylated TagBFP and EYFP, both in reverse orientation between mutant Lox sites. These AAV preparations are suitable purity for injection into animals.

Dawen Cai, Joshua Sanes

Cai et al Nat Methods. 2013 May 5;10(6):540-7. doi

March 7, 2018

Academic Institutions and Nonprofits only

#18916-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-rev-ChR2(H134R)-mCherry (#18916). In addition to the viral particles, you will also receive purified AAV-FLEX-rev-ChR2(H134R)-mCherry plasmid DNA. CAG-driven, cre-dependent, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Atasoy et al J Neurosci. 2008 Jul 9. 28(28):7025-30.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#218877-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#28305-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-ArchT-tdTomato (#28305). In addition to the viral particles, you will also receive purified pAAV-FLEX-ArchT-tdTomato plasmid DNA. CAG-driven Cre-dependent ArchT-tdTomato expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#112010-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#218877-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2-WPRE (#218877). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor iGABASnFR2 (positive change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Sept. 27, 2024

Academic Institutions and Nonprofits only

#112010-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-FLEx-axon-GCaMP6s (#112010). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-FLEx-axon-GCaMP6s plasmid DNA. Synapsin-driven, cre-dependent axon-targeted GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 2, 2019

Academic Institutions and Nonprofits only

#169128-AAV1

Ready-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.

Georg Nagel

Zhang et al Nature. 2021 Sep;597(7875):245-249. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#22222-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#218879-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE (#218879). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Oct. 21, 2024

Academic Institutions and Nonprofits only

#218879-AAV5

Ready-to-use AAV5 particles produced from pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE (#218879). In addition to the viral particles, you will also receive purified pGP-AAV-syn-flex-iGABASnFR2(no bind)-WPRE plasmid DNA. Syn-driven, Cre-dependent expression of the improved GABA sensor control iGABASnFR2(no bind) (no change in fluorescence). These AAV preparations are suitable purity for injection into animals.

GENIE Project

Kolb et al bioRxiv 2025.03.25.644953

Oct. 21, 2024

Academic Institutions and Nonprofits only

#71760-AAV1

Ready-to-use AAV1 particles produced from pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby (#71760). In addition to the viral particles, you will also receive purified pAAV hSyn FLEx mGFP-2A-Synaptophysin-mRuby plasmid DNA. Syn-driven, Cre-dependent expression of membrane-bound GFP and the presynaptic protein synaptophysin fused to mRuby. These AAV preparations are suitable purity for injection into animals.

Liqun Luo

Beier et al Cell. 2015 Jul 30;162(3):622-34. doi: 10

May 5, 2021

Academic Institutions and Nonprofits only

#137119-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-Con/Fon-GCaMP6M (#137119). In addition to the viral particles, you will also receive purified pAAV-EF1a-Con/Fon-GCaMP6M plasmid DNA. EF1a-driven, Cre and Flp-dependent expression of GCaMP6M. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Sept. 24, 2020

Academic Institutions and Nonprofits only

#55636-AAV11

Ready-to-use AAV11 particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 16, 2025

Academic Institutions and Nonprofits only